Nuclea is a translational medicine company dedicated to the discovery of proprietary biomarkers and in vitro companion diagnostic assays based on corresponding gene and protein expression profiles associated with an individual's tumor or specific disease state. Nuclea's differentiated DecisionDx^TM platform technology greatly improves the efficiency of genomic discovery by utilizing proprietary software in the genetic and molecular analysis of a biorepository of 150,000 highly characterized clinical patient samples. The Company has applied these discovery efforts to the development of in vitro companion diagnostics for use in therapeutic and medical imaging applications across the five major cancer types: colon, stomach, leukemia, lung and prostate. Nuclea is also utilizing its DecisionDx^TM platform technology to develop companion diagnostics for other disease indications such as cardiovascular, neurological, inflammation and metabolic disorders.